Showing 1 posts of 1 posts found.
Endo is switching strategies from attempting to buy specialist pharma firms, to generics, having announced a huge $8 billion deal …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO